New drug combo targets tough ovarian cancer in early trial

NCT ID NCT06964009

Recruiting now Disease control Sponsor: Elizabeth Stover, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called DT2216 combined with the chemotherapy paclitaxel in people whose ovarian cancer has returned and is resistant to platinum-based treatments. The main goal is to find the highest safe dose of DT2216 when given with paclitaxel. About 30 participants will receive the combination to see how well it controls the cancer and what side effects occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER OVARIAN CARCINOMA RECURRENT OVARY CANCER RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center (BIDMC)
RECRUITING

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.